About Furiex Drug Development Programs
Furiex Pharmaceuticals, Inc., a subsidiary of Actavis plc, is a drug development company focusing on treatment for gastroenterology disorders.
EXPERT. FOCUSED. FAST.
02 Sep >> Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline More details >
02 Jul >> Actavis Completes Acquisition of Furiex Pharmaceuticals More details >
01 Jul >> Furiex Stockholders Approve Acquisition by Actavis; Ukrainian Antimonopoly Committee Clears Proposed Merger More details >
FURIEX PARTNER PIPELINE
Furiex has a strong, diversified product portfolio and pipeline with four products approved/marketed and two clincial development programs in late-stage development.